Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis

The discovery and development of new treatments for Alzheimer's disease (AD) requires a profound mechanistic understanding of the disease. Here, we propose a model‐driven approach supporting the systematic identification of putative disease mechanisms.

[1]  Chengbiao Wu,et al.  Current advances in using neurotrophic factors to treat neurodegenerative disorders , 2012, Translational Neurodegeneration.

[2]  F. Polleux,et al.  Terminal Axon Branching Is Regulated by the LKB1-NUAK1 Kinase Pathway via Presynaptic Mitochondrial Capture , 2013, Cell.

[3]  B. Zlokovic,et al.  Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[4]  David Eisenberg,et al.  In Brief , 2009, Nature Reviews Neuroscience.

[5]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[6]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[8]  A. Goate,et al.  Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains , 2012, PloS one.

[9]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[10]  M. Danik,et al.  Possible functions of a new genetic marker in central nervous system: The sulfated glycoprotein‐2 (SGP‐2) , 1992, Synapse.

[11]  Stephen B. Montgomery,et al.  Detection and Impact of Rare Regulatory Variants in Human Disease , 2013, Front. Genet..

[12]  C. Cotman,et al.  β-Amyloid (Aβ) Oligomers Impair Brain-derived Neurotrophic Factor Retrograde Trafficking by Down-regulating Ubiquitin C-terminal Hydrolase, UCH-L1* , 2013, The Journal of Biological Chemistry.

[13]  Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK α2-subunit (PRKAA2) and risk of type 2 diabetes , 2008 .

[14]  R. Shaw,et al.  LKB1 and AMP‐activated protein kinase control of mTOR signalling and growth , 2009, Acta physiologica.

[15]  Natalie L. Catlett,et al.  Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data , 2013, BMC Bioinformatics.

[16]  R. Green,et al.  Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. , 2006, Archives of neurology.

[17]  A. López-Bermejo,et al.  A Single Nucleotide Polymorphism in STK11 Influences Insulin Sensitivity and Metformin Efficacy in Hyperinsulinemic Girls With Androgen Excess , 2010, Diabetes Care.

[18]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[19]  H. Soininen,et al.  AMP‐activated protein kinase: a potential player in Alzheimer’s disease , 2011, Journal of neurochemistry.

[20]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[21]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[22]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[23]  Takeo Kato,et al.  Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.

[24]  Gary D Bader,et al.  A travel guide to Cytoscape plugins , 2012, Nature Methods.

[25]  Frédéric Baribaud,et al.  Genes Associated with Intestinal Permeability in Ulcerative Colitis: Changes in Expression Following Infliximab Therapy , 2012, Inflammatory bowel diseases.

[26]  Junfa Li,et al.  Downregulation of miR‐181b in mouse brain following ischemic stroke induces neuroprotection against ischemic injury through targeting heat shock protein A5 and ubiquitin carboxyl‐terminal hydrolase isozyme L1 , 2013, Journal of neuroscience research.

[27]  L. Hazrati,et al.  Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains , 2013, Clinical Proteomics.

[28]  Eric M Reiman,et al.  Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. , 2007, Physiological genomics.

[29]  C. Akar,et al.  Amyloid precursor protein modulates the interaction of nerve growth factor with p75 receptor and potentiates its activation of trkA phosphorylation. , 1998, Brain research. Molecular brain research.

[30]  Diego Megias,et al.  Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. , 2013, Endocrine-related cancer.

[31]  Martin Hofmann-Apitius,et al.  Mining biomarker information in biomedical literature , 2012, BMC Medical Informatics and Decision Making.

[32]  Martin Hofmann-Apitius,et al.  Linking hypothetical knowledge patterns to disease molecular signatures for biomarker discovery in Alzheimer’s disease , 2014, Genome Medicine.

[33]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[34]  K. Siddle.  Signalling by insulin and IGF receptors: supporting acts and new players. , 2011, Journal of molecular endocrinology.

[35]  T. Suuronen,et al.  Clusterin: A forgotten player in Alzheimer's disease , 2009, Brain Research Reviews.

[36]  T. Egashira,et al.  Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. , 2006, Journal of atherosclerosis and thrombosis.

[37]  Jing Zhu,et al.  Apparently low reproducibility of true differential expression discoveries in microarray studies , 2008, Bioinform..

[38]  M. Arevalo,et al.  Amyloid β serves as an NGF‐like neurotrophic factor or acts as a NGF antagonist depending on its concentration , 2009, Journal of neurochemistry.

[39]  J. Moscat,et al.  TRAF6 and p62 inhibit amyloid β-induced neuronal death through p75 neurotrophin receptor , 2012, Neurochemistry International.

[40]  D. Carling.  LKB1: a sweet side to Peutz-Jeghers syndrome? , 2006, Trends in molecular medicine.

[41]  Ling Xie,et al.  Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor , 2002, The Journal of Neuroscience.

[42]  Brian Lawlor,et al.  Genome-wide Association Study of Alzheimer’s disease with Psychotic Symptoms , 2011, Molecular Psychiatry.

[43]  S. Bassett,et al.  Alzheimer's risk variants in the clusterin gene are associated with alternative splicing , 2011, Translational Psychiatry.

[44]  Thomas Manke,et al.  ChroMoS: an integrated web tool for SNP classification, prioritization and functional interpretation , 2013, Bioinform..

[45]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[46]  Dan Zhang,et al.  The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits , 2012, Neurobiology of Aging.

[47]  M. Ciotti,et al.  Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation , 2009, Proceedings of the National Academy of Sciences.

[48]  M. Lawrence,et al.  Ligand‐induced activation of the insulin receptor: a multi‐step process involving structural changes in both the ligand and the receptor , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[49]  A. Miyashita,et al.  A Map of Alzheimer's Disease–Signaling Pathways: A Hope for Drug Target Discovery , 2013, Clinical pharmacology and therapeutics.

[50]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[51]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.